Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-<i>Acinetobacter baumannii</i>outer membrane protein A fusion proteins against renal cell carcinoma

Kim, B.-R.; Yang, Eun Kyoung; Kim, D.-Y.; Kim, S.-H.; Moon, Dong Chan; Lee, J.-H.; Kim, H.-J.; Lee, J.-C.

doi:10.1111/j.1365-2249.2011.04489.x

Cited by 14 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16] The aim of active specific immunotherapy is to establish a highly selective and potent cellular immune response, specifically directed against the patient's cancer cells. Dendritic cells (DCs) are the most potent antigen presenting cells with an ability to prime both a primary and secondary immune response to tumor cells.…”

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15] DC vaccine has the ability to start and amplify antigen-specific anti-tumor responses. [16][17][18] Once the immune system generates T-cells specific for a particular antigen of CRC cell, a group of immune memory cells that remember this antigen will remain in the body. In the case of a second threat from the same antigen, an immune response will be mounted much faster than the first one vaccination, stimulates the immune system to kill residual cancer cells that persist in the body and could result in the cancer recurring and metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic cell vaccine treatment of advanced de novo colorectal cancer in renal transplant patients

Ying¹,

Yang²,

Hao³

et al. 2014

Indian J Cancer

View full text Add to dashboard Cite

Objective: The clinical outcome, especial the immunologic responses to cancer and graft, of dendritic cell (DC) vaccine in the treatment of advanced de novo colorectal cancer (CRC) in renal transplant patients was investigated in this study. Materials and Methods: 7 patients were received 1 cycle tumor lysate pulsed autologous DC vaccine. The positive cell-mediated cytotoxicity responses to DC vaccine against CRC cell in two out of 7 patients were seen by delayed type hypersensitivity (DTH) test. The positive cell-mediated cytotoxicity responses to DC vaccine against normal kidney cell in all 7 patients were not seen by DTH tests and no notable change of renal function during and after vaccination. Conclusions: DC vaccine has emerged as a promising new strategy in the treatment of advanced de novo CRC in renal transplant patients and DC vaccines have become an attractive therapeutic option, developing immune responses specific against CRC cell, achieving clinical efficacy without graft failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dendritic cell vaccine treatment of advanced de novo colorectal cancer in renal transplant patients

Ying¹,

Yang²,

Hao³

et al. 2014

Indian J Cancer

View full text Add to dashboard Cite

show abstract

“…The main one was the use of dendritic cells (DCs, specific tumor antigen presentation) via an introduction of a granulocyte-macrophage colony stimulating factor (GMCSF)-CAIX fusion protein (produced by viral bioengineering), in order to activate DCs and thus trigger a CD8+ mediated, CAIX targeted, antitumoral response. Kim et al [ 50 ] presented the results of a pre-clinical study in 2011 aiming to activate DCs by a combination of CAIX and Acinetobacter baumannii outer membrane protein A (AbOmpA) in a murine model [ 51 ]. A significant immunostimulatory of DCs was observed via secretion of IL-2 and interferon (IFN)γ in T-cells.…”

Section: Evidence Synthesismentioning

confidence: 99%

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management

Courcier

Taille

Nourieh

et al. 2020

IJMS

View full text Add to dashboard Cite

Carbonic Anhydrase IX (CAIX) is a well-described enzyme in renal cell carcinoma, with its expression being regulated by the hypoxia-inducible factor 1 alpha, it is known for interfering with hypoxia processes. Renal carcinoma encompasses a broad spectrum of histological entities and is also described as a heterogeneous malignant tumor. Recently, various combinations of checkpoint inhibitors and targeted therapies have been validated to manage this disease. Reliable markers to confirm the diagnosis, estimate the prognosis, predict or monitor the treatment response are required. Molecular imaging developments allow a comprehensive analysis of the tumor, overcoming the spatial heterogeneity issue. CAIX, being highly expressed at the tumor cell surfaces of clear cell renal carcinoma, also represents a potential treatment target. In this manuscript we reviewed the current knowledge from the literature on the pathophysiological interactions between renal cell carcinoma and CAIX, the role of CAIX as a marker for diagnosis, prognosis, treatment monitoring and molecular imaging, and the potential target for therapeutic strategies.

show abstract

“…Eight of them were devoted to therapeutic DC-based vaccines, where DCs were administered to tumor-bearing mice, four studies focused on preventive DC-based vaccines with DCs administered to animals before tumor grafting, and three studies were devoted to both types of DC-based vaccines. The antitumor potential of DCs was studied in murine tumor models such as colorectal cancer [ 47 , 48 ], hepatocellular carcinoma [ 49 , 50 ], Dalton’s lymphoma [ 51 ] and EL4 lymphoma [ 52 ], FBL3 leukemia[ 53 ], 4T1 breast carcinoma [ 54 ], B16 melanoma [ 30 , 55 - 57 ], Lewis lung carcinoma [ 58 , 59 ], and SCCVII squamous cell lung cancer models [ 60 ] ( Table 1 ). In almost all the publications under analysis, DCs were prepared by incubation of bone marrow-derived pre-DCs in the presence of the cytokines GM-CSF and IL-4.…”

Section: In Vivo Efficacy Of Dc-based Vaccines In Murine Modelsmentioning

confidence: 99%

Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials

et al. 2017

View full text Add to dashboard Cite

The routine methods used to treat oncological diseases have a number of drawbacks, including non-specific action and severe side effects for patients. Furthermore, tumor diseases are associated with a suppression of the immune system that often leads to the inefficiency of standard treatment methods. The development of novel immunotherapeutic approaches having specific antitumor action and that activate the immune system is of crucial importance. Vaccines based on dendritic cells (DCs) loaded with tumor antigens ex vivo that can activate antitumor cytotoxic T-cell responses stand out among different antitumor immunotherapeutic approaches. This review is focused on analyzing different methods of DC-based vaccine preparation and current research in antitumor DC-based vaccines using animal tumor models and in clinical trials.

show abstract

Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumanniiouter membrane protein A fusion proteins against renal cell carcinoma

Cited by 14 publications

References 36 publications

Dendritic cell vaccine treatment of advanced de novo colorectal cancer in renal transplant patients

Dendritic cell vaccine treatment of advanced de novo colorectal cancer in renal transplant patients

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management

Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials

Contact Info

Product

Resources

About